Clinical Trials

21 enrolled

Stomach Neoplasms

NCT03708822 2024-01-18

Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

48 enrolled

Nasopharyngeal Carcinoma

NCT03646968 2023-12-27

SAVE

43 enrolled

Non-Squamous Non Small Cell Lung Cancer

NCT06182800 2023-12-27

Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy

Carcinoma, Non-Small-Cell Lung

NCT05262335 2023-11-28

ALTER-G-001

116 enrolled

Digestive System Neoplasms

NCT06107114 2023-11-22

CZCNRHNSCC

52 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04999332 2023-11-15

LOTS

58 enrolled

Stomach Neoplasms

NCT06130007 2023-11-13

B2023-153

48 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05863325 2023-11-07

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04165993 2023-09-21

Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

68 enrolled

Breast Neoplasms

NCT06023875 2023-09-05

NCCCNRHNSCC

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04156698 2023-08-09

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

51 enrolled

Hypopharyngeal Neoplasms

NCT02679040 2023-07-03

HIST-RIC

101 enrolled

Breast Neoplasms

NCT02760667 2023-06-27

Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer

20 enrolled

Head and Neck Neoplasms, Laryngeal Neoplasms, Oropharyngeal Neoplasms

NCT04819971 2023-04-25

Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC

67 enrolled

Stomach Neoplasms

NCT05616494 2023-03-22

A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer

53 enrolled

Pancreatic Neoplasms

NCT05769725 2023-03-15

A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer

70 enrolled

Stomach Neoplasms

NCT02099175 2023-03-13

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients

41 enrolled

Sinonasal Tumors

NCT02099188 2023-03-13

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients

27 enrolled

Unresectable Sinonasal Tumors

NCT05549466 2023-02-08

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

84 enrolled

Nasopharyngeal Carcinoma

NCT05705635 2023-01-31

A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

100 enrolled

Gastric Adenocarcinoma

NCT04869371 2022-12-29

Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer

75 enrolled

Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel

NCT05611463 2022-11-10

CHANCE

25 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05461261 2022-10-24

The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer

50 enrolled

Hormone Sensitive Metastatic Prostate Cancer

NCT05325229 2022-10-13

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

94 enrolled

Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

NCT05483439 2022-08-05

A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

100 enrolled

Breast Neoplasms

NCT04881929 2022-06-22

Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

30 enrolled

Breast Neoplasms

NCT05400993 2022-06-06

Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC

59 enrolled

Breast Neoplasms

NCT04878107 2022-05-02

SABRE

88 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05158062 2022-04-26

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT05322499 2022-04-11

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

80 enrolled

Esophageal Squamous Cell Carcinoma

NCT03061643 2022-03-08

An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma

42 enrolled

Prostatic Neoplasms

NCT05192681 2022-01-14

Tislelizumab as Cross-line Treatment for Advanced NSCLC

Advanced Non-small-cell Lung Cancer

NCT03238495 2021-12-07

HERMET

100 enrolled

HER2-positive Breast Cancer

NCT03830411 2021-11-08

A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy

76 enrolled

Nonsquamous Non-Small Cell Lung Cancer

NCT03863483 2021-11-08

A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.

70 enrolled

Nonsquamous Non-Small Cell Lung Cancer

NCT04367909 2021-11-08

A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma

68 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05088057 2021-10-21

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

30 enrolled

Triple Negative Breast Neoplasms

NCT05008237 2021-08-17

Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study

42 enrolled

Salivary Gland Neoplasms

NCT04717531 2021-06-04

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

60 enrolled

Breast Neoplasms

NCT04760431 2021-06-02

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

120 enrolled

CNS

Brain Neoplasms

NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Metastatic Gastric Adenocarcinoma

NCT04563975 2021-03-17

Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer

54 enrolled

Stomach Neoplasms

NCT04603833 2021-02-21

A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

150 enrolled

Prostate Cancer Metastatic

NCT04354662 2021-02-18

Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer

Stomach Neoplasms

NCT04757779 2021-02-17

A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer

40 enrolled

Small Cell Lung Carcinoma

NCT01359397 2021-01-27

B-DOCT

Stomach Neoplasms

NCT03432780 2021-01-22

QRT-SOGUG

134 enrolled

Prostatic Neoplasms

NCT03154983 2020-12-09

The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer

48 enrolled